TD Cowen Initiates Coverage On NewAmsterdam Pharma with Buy Rating
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tyler Van Buren has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating.
May 15, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Tyler Van Buren has initiated coverage on NewAmsterdam Pharma with a Buy rating, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating by a reputable analyst can lead to increased investor interest and buying activity, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100